Taking CFTR modulators as a child may make boys and girls with cystic fibrosis (CF) grow about a third of an inch taller by the time they turn 18, according to a large study of data from the CF Foundation patient registry. Researchers also observed that being taller…
News
Restless legs syndrome (RLS), a disorder characterized by an irresistible urge to move legs or other body parts, especially during sleep, is highly prevalent among adults with cystic fibrosis (CF), a study shows. A higher percentage of hemoglobin A1c, or HbA1c, indicative of CF-related diabetes (CFRD), and…
People with cystic fibrosis (CF) who have chronic inflammation in the nose are less likely to need sinus surgery if they are taking the triple-combination CFTR modulator treatment Kaftrio (elexacaftor/tezacaftor/ivacaftor). That’s according to “Triple combination CFTR modulator therapy reduces the need for endoscopic sinus surgery…
Inflammatory molecules that serve as markers of infection or other problems can be measured in the nasal fluid of babies with cystic fibrosis (CF), collected using filter paper placed in a nostril. Changes in the levels of some of these molecules, using this noninvasive method, were seen in infants…
Structural improvements in the airways and sinuses of adults with cystic fibrosis (CF) were seen on CT scans after a year on Kaftrio, and occurred alongside reductions in CF symptoms and gains in measures of lung function, according to an Italian study. “Imaging findings on CT during…
Researchers have developed a lab model of a cystic fibrosis (CF) lung infection that can help inform how antibiotic-resistant infections arise and to test antimicrobial treatment candidates. A human phlegm-like substance was generated where multiple types of microbes were able to grow into three-dimensional (3D) biofilms, the protective clusters…
Health Canada has extended its approval of Kalydeco (ivacaftor) to treat children as young as 2 months and weighing at least three kilograms, or about 6.6 pounds, who have cystic fibrosis (CF) caused by mutations that are responsive to the medicine. The extension covers patients who carry at…
Epithelial cells — the protective cells that line the airways — taken from people with cystic fibrosis (CF) exhibited distinct cellular and genetic features in lab cultures depending on whether they were obtained from the upper or lower airways, according to recent research. Those differences corresponded to distinct fluid-secreting…
BX004, an inhaled phage therapy being developed for chronic Pseudomonas aeruginosa lung infections, led to clinically meaningful improvements in lung function for cystic fibrosis (CF) patients with existing lung impairments, according to top-line results from the Phase 2 part of an ongoing Phase 1b/2a clinical trial. The therapy…
The U.S. Food and Drug Administration (FDA) has granted orphan drug status to ARCT-032, Arcturus Therapeutics’ inhaled experimental treatment for cystic fibrosis (CF). The designation is intended to encourage the development of therapies for rare diseases, or those affecting fewer than 200,000 people in the U.S. It provides incentives,…
Your CF Community
Visit the Cystic Fibrosis News Today forums to connect with others in the CF community.